ANI Pharmaceuticals Posts 3Q Adjusted EPS of $2.70
ANIP is trading near its 52-week low of $69.58 (3.5% above the low).
Summary
ANI Pharmaceuticals reported third-quarter adjusted EPS of $2.70, against an IBES estimate of USD 2.18. The print lands with the stock near its 52-week low of $69.58, so the bar for a positive reaction is low after August's cut to the Cortrophin Gel revenue outlook. The same morning, ANI disclosed an offer to acquire Egetis Therapeutics at SEK 11.25 per share, which is the bigger story for the equity today. The headline gives only the adjusted EPS line, with no revenue, GAAP figure, or updated guidance, so the quality of the beat or miss cannot be judged from this alone.
At the time of this announcement, ANIP was trading at $72.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $69.58 to $95.57. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.